The 2025 Wuhan Investment Promotion Conference took place on Dec 18, attracting around 240 representatives from Fortune Global 500 companies, multinational corporations, tech-innovative enterprises, and business associations. A series of key projects were signed on-site, totaling 110.97 billion yuan ($15.76 billion).

Wuhan East Lake High-tech Development Zone (Optics Valley of China, or OVC) secured agreements for 11 major projects, including the United Imaging Global High-End Medical Equipment Innovation and Manufacturing Base and the Darwin Cell Biotech Innovative Drug R&D and Production Base, with contracts totaling more than 20 billion yuan.

The 2025 Wuhan Investment Promotion Conference in Wuhan. [Photo/WeChat account of Optics Valley of China]

Wuhan's top 10 most influential investment projects for 2025 were announced, with two key OVC projects on the list.

The Jiangcheng Laboratory Advanced Packaging Comprehensive Experimental Platform and Industrialization Base project aims to establish a leading domestic platform for advanced integrated-circuit packaging. The headquarters and innovative drug R&D and production base of Forward Pharmaceuticals will focus on developing next-generation small-molecule anti-tumor drugs.

Company representatives at the event praised Wuhan's business environment. Xue Min, chairman of United Imaging Group, highlighted the city's strong foundation in science and education, abundant medical resources, robust interdisciplinary strengths, and favorable innovation ecosystem. 

United Imaging, having already invested over 7 billion yuan in Wuhan, plans to invest an additional 7 billion yuan in OVC over the next five years to build a global high-end medical equipment innovation and manufacturing base.